Altis Biosystems

ALTIS BIOSYSTEMS

Biotechnology, 1289 Fordham Boulevard, Chapel Hill, North Carolina, 27514, United States 11-50 Employees

altisbiosystems.com

  • Linkedin

Who is ALTIS BIOSYSTEMS

Altis has developed a patent-pending stem cell technology recreating the human intestinal epithelium for compound screening and microbiome research. The product is called RepliGut. It will a.....

Read More
map
  • 1289 Fordham Boulevard, Chapel Hill, North Carolina, 27514, United StatesHeadquarters: 1289 Fordham Boulevard, Chapel Hill, North Carolina, 27514, United States
  • 2015Date Founded: 2015
  • employee-count-iconEmployees: 11-50
  • dollar-iconRevenue: $5 Million to 10 Million
  • tech-iconActive Tech Stack: See technologies

industries-iconIndustry: Biotechnology

8731SIC Code: 8731 | NAICS Code: 541713 | Show More

checked-iconDoes something look wrong? Fix it. | View contact records from ALTIS BIOSYSTEMS

View Employees

Niki Heinz

Niki Heinz

Director Of Business Development

Bailey Zwarycz

Bailey Zwarycz

Associate Director Of Commercial Services

Similar Companies to Altis Biosystems

Biomiga

  • 11-5011-50
  • dollar-icon$ 5 Million to 10 Million

Dyve Biosciences

  • 11-5011-50
  • dollar-icon$ 5 Million to 10 Million

Amulet

  • 11-5011-50
  • dollar-icon$ 5 Million to 10 Million

Altis Biosystems Activity Score

signout-image
You are signed out

Sign in to CIENCE GO Data to uncover contact details

crown-iconFree credits every month

Frequently Asked Questions Regarding Altis Biosystems

Answer: Altis Biosystems's headquarters are located at 1289 Fordham Boulevard, Chapel Hill, North Carolina, 27514, United States

Answer: Altis Biosystems's official website is altisbiosystems.com

Answer: Altis Biosystems is in the industry of: Biotechnology

Answer: Altis Biosystems contact info: Phone number: _***** Website: Altisbiosystems.com

Answer: Altis has developed a patent-pending stem cell technology recreating the human intestinal epithelium for compound screening and microbiome research. The product is called RepliGut. It will allow drugs to be tested on an in vitro platform that more closely mimics native human biology. Our goal is to enable pharmaceutical companies to identify effective compounds earlier, before clinical trials; to reduce animal testing; and to make the drug development process faster, cheaper, and safer. Currently, 88% of drugs fail during clinical trials. Part of the reason is that during preclinical studies, drugs are tested using tumor cells and animals. These cannot accurately indicate the way that pharmaceuticals will behave in the human body. The current market lacks a viable method for testing drugs, prior to human testing, and RepliGut will more accurately reflect drug behavior in humans.

Answer:

View Employees

Niki Heinz

Niki Heinz

Director Of Business Development

Bailey Zwarycz

Bailey Zwarycz

Associate Director Of Commercial Services

Altis Biosystems Activity Score

signout-image
You are signed out

Sign in to CIENCE GO Data to uncover contact details

icon-imageFree credits every month